High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort

Delphine Marotte,Jocelyn Gal,Renaud Schiappa,Mathieu Gautier,Rabia Boulahssass,Marie-Eve Chand-Fouche,Jean-Michel Hannoun-Levi

Clinical and Translational Radiation Oncology（2022）

Cited 2|Views11

No score

Abstract

•Intermediate/high risk elderly prostate cancer benefits less from received standards of care.•Age is an independent factor for disease control and tolerance.•Brachytherapy boost remains efficient and feasible in the elderly.•Careful discussion for super elderly patients (>80 y) is warranted.•Oncogeriatric assessment is necessary to identify best candidates.

Translated text

Key words

ADT,BT,bRFS,CSS,CT,CTCAE,CTV,D2cc,D90,D100,DFS,DNR,EBRT,EQD2,GI,GU,HDB,HR,IMRT,IR,ISUP,LDR,LR,lRFS,MFU,mRFS,MRI,NCCN,OAR,OS,PC,PET,PSA,pts,QoL,RCT,rRFS,TD,V100,V150,V200,Vr90,Vr100,Vu115,Vu125,3DRT

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined